Growing Adoption of Advanced Treatment Options to Drive Growth of the PCOS Treatment Market
%20Treatment%20Market.jpg) |
| Polycystic Ovary Syndrome (PCOS) Treatment Market |
The Polycystic Ovary Syndrome (PCOS) Treatment Market is
estimated to be valued at US$ 1,086.6
million in 2023 and is expected to exhibit a 4.86% CAGR over the forecast period 2023-2030, as highlighted in a new report published by Coherent
Market Insights.
Market
Overview:
Polycystic ovary syndrome (PCOS) is one of the most common endocrine system
disorders in women of reproductive age that can affect their menstrual cycle,
fertility and increase long-term health risks like diabetes and heart disease.
Oral contraceptives, ovulation induction agents and antibiotics are commonly
prescribed to treat symptoms and reduce health risks.
Market
Dynamics:
The increasing awareness about PCOS and availability of advanced treatment
options are expected to drive the market growth over the forecast period. The
rising adoption of metformin and oral contraceptives for managing symptoms and
preventing long-term complications is fueling the market. Additionally,
adoption of innovative therapies like laparoscopic ovarian drilling procedures
and weight management programs for lifestyle changes are gaining popularity,
thus supporting the market expansion.
Market key
trends:
The polycystic ovary syndrome (PCOS) treatment market is witnessing high growth
owing to increasing adoption of off-label drugs to treat PCOS symptoms.
Conventionally, metformin has been the first line of treatment for PCOS.
However, off-label drugs like anti-depressants, oral contraceptives, and
spironolactone are also increasingly prescribed by doctors to fight problems
like excess hair growth, acne, weight gain, and irregular periods associated
with PCOS. The use of off-label medications is driven by their effectiveness in
managing multiple PCOS symptoms simultaneously.
SWOT Analysis
Strength: High unmet medical needs associated with PCOS management. PCOS
treatment mainly focuses on symptoms control rather than finding a cure.
Weakness: Limited options for drugs approved specifically for PCOS treatment.
Most treatments involve off-label use of existing drugs.
Opportunity: Growth in R&D activities for development of novel and targeted
therapies. Investments into understanding PCOS pathogenesis can lead to more
effective treatments.
Threats: Safety concerns over long-term use of off-label medications prescribed
for PCOS. High development costs associated with drugs targeting a woman's
health issue.
Key Takeaways
The Global
Polycystic Ovary Syndrome (PCOS) Treatment Market Size was valued at US$ 1,086.6 million in 2023. The market
is expected to grow at a substantial CAGR
of 4.86% during the forecast period of 2023-2030.
The high prevalence of PCOS worldwide is a key factor driving increased demand
for effective treatment options.
Regional analysis: The United States represents the largest regional market,
owing to rising PCOS diagnosis, developed healthcare infrastructure, and
growing awareness about available treatments. Europe is also among the
prominent markets globally supported by increasing healthcare spending.
Key players: Key players operating in the polycystic ovary syndrome (PCOS)
treatment market include Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs
Limited, Zydus Pharmaceuticals, Inc., Prasco Laboratories, Dr. Reddy's
Laboratories, Cadila Pharmaceuticals, Novartis International AG, Concordia Pharmaceuticals
Inc., Covis Pharmaceuticals, Inc., Cardinal Health, Aphena Pharma Solutions
Tennessee, Inc., Mylan N.V., Evotec SE, McKesson Corporation, Teva
Pharmaceutical Industries Ltd, Lupin Pharmaceutical and Sun Pharmaceutical
Industries Ltd., Bayer AG.
Comments
Post a Comment